{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:38:18Z","timestamp":1787981898478,"version":"build-2784847793"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-tuberculous mycobacterial pulmonary disease (NTM-PD) is increasing worldwide, with Mycobacterium avium complex (MAC) and Mycobacterium abscessus as the predominant pathogens. Current treatments are poorly tolerated and modestly effective, highlighting the need for new treatments. SPR719, the active moiety of the benzimidazole prodrug SPR720, inhibits the ATPase subunits of DNA gyrase B, a target not exploited by current antibiotics, and therefore, no cross-resistance is expected with standard-of-care (SOC) agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the in vitro activity of SPR719 against MAC and M. abscessus clinical isolates, including those resistant to SOC agents, and in vivo efficacy of SPR720 in murine non-tuberculous mycobacteria (NTM) pulmonary infection models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>NTM isolates were tested for susceptibility to SPR719. Chronic C3HeB\/FeJ and severe combined immunodeficient murine models of pulmonary infection were used to assess efficacy of SPR720 against MAC and M. abscessus, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SPR719 was active against MAC (MIC90, 2\u2005mg\/L) and M. abscessus (MIC90, 4\u2005mg\/L) clinical isolates. Efficacy of SPR720 was demonstrated against MAC pulmonary infection, both as a monotherapy and in combination with SOC agents. SPR720 monotherapy exhibited dose-dependent reduction in bacterial burden, with the largest reduction observed when combined with clarithromycin and ethambutol. Efficacy of SPR720 was also demonstrated against M. abscessus pulmonary infection where monotherapy exhibited a dose-dependent reduction in bacterial burden with further reductions detected when combined with SOC agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In vitro activity of SPR720 against common NTM pathogens and efficacy in murine infections warrant the continued clinical evaluation of SPR720 as a new oral option for the treatment of NTM-PD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkae046","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T16:17:08Z","timestamp":1707149828000},"page":"875-882","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of SPR720 in murine models of non-tuberculous mycobacterial pulmonary infection"],"prefix":"10.1093","volume":"79","author":[{"given":"Nicole","family":"Cotroneo","sequence":"first","affiliation":[{"name":"Spero Therapeutics, Inc. , 675 Massachusetts Avenue, 14th Floor, Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne S","family":"Stokes","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Inc. , 675 Massachusetts Avenue, 14th Floor, Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Pucci","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Inc. , 675 Massachusetts Avenue, 14th Floor, Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Rubio","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Inc. , 675 Massachusetts Avenue, 14th Floor, Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1896-9736","authenticated-orcid":false,"given":"Kamal A","family":"Hamed","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Inc. , 675 Massachusetts Avenue, 14th Floor, Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A","family":"Critchley","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Inc. , 675 Massachusetts Avenue, 14th Floor, Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"2025120411373932800_dkae046-B1","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1093\/infdis\/jiaa354","article-title":"Mycobacterium avium complex: addressing gaps in diagnosis and management","volume":"222","author":"Daley","year":"2020","journal-title":"J Infect Dis"},{"key":"2025120411373932800_dkae046-B2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1513\/AnnalsATS.201412-559OC","article-title":"Population-based incidence of pulmonary nontuberculous mycobacterial disease in Oregon 2007 to 2012","volume":"12","author":"Henkle","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"2025120411373932800_dkae046-B3","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3201\/eid2310.170845","article-title":"Surveillance of extrapulmonary nontuberculous mycobacteria infections, Oregon, USA, 2007\u20132012","volume":"23","author":"Henkle","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2025120411373932800_dkae046-B4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2025120411373932800_dkae046-B5","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.chest.2021.10.048","article-title":"Impact of time between diagnosis and treatment for nontuberculous mycobacterial pulmonary disease on culture conversion and all-cause mortality","volume":"161","author":"Im","year":"2022","journal-title":"Chest"},{"key":"2025120411373932800_dkae046-B6","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","article-title":"Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review","volume":"153","author":"Diel","year":"2018","journal-title":"Chest"},{"key":"2025120411373932800_dkae046-B7","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1378\/chest.15-0543","article-title":"Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and\/or rifampin","volume":"149","author":"Jarand","year":"2016","journal-title":"Chest"},{"key":"2025120411373932800_dkae046-B8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.chest.2021.07.035","article-title":"Treatment of Mycobacterium abscessus pulmonary disease","volume":"161","author":"Griffith","year":"2022","journal-title":"Chest"},{"issue":"Suppl 1","key":"2025120411373932800_dkae046-B9","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jfma.2020.05.028","article-title":"Treatment for Mycobacterium abscessus complex-lung disease","volume":"119","author":"Weng","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"2025120411373932800_dkae046-B10","doi-asserted-by":"crossref","first-page":"e01503-18","DOI":"10.1128\/AAC.01503-18","article-title":"In vitro susceptibility testing of a novel benzimidazole, SPR719, against nontuberculous mycobacteria","volume":"62","author":"Brown-Elliott","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120411373932800_dkae046-B11","doi-asserted-by":"crossref","first-page":"e02469-20","DOI":"10.1128\/AAC.02469-20","article-title":"The benzimidazole SPR719 shows promising concentration-dependent activity and synergy against nontuberculous mycobacteria","volume":"65","author":"Pennings","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120411373932800_dkae046-B12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3343\/alm.2024.44.1.92","article-title":"In vitro activity of benzimidazole (SPR719) against clinical isolates of nontuberculous mycobacteria with and without clarithromycin or amikacin resistance","volume":"44","author":"Kim","year":"2024","journal-title":"Ann Lab Med"},{"key":"2025120411373932800_dkae046-B13","doi-asserted-by":"crossref","first-page":"S817","DOI":"10.1093\/ofid\/ofaa439.1837","article-title":"Pharmacokinetics\/pharmacodynamics of the novel gyrase inhibitor SPR719\/SPR720 and clinical dose selection to treat pulmonary Mycobacterium avium-complex disease","volume":"7","author":"Deshpande","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2025120411373932800_dkae046-B14","doi-asserted-by":"crossref","first-page":"e0120821","DOI":"10.1128\/AAC.01208-21","article-title":"First-in-human evaluation of the safety, tolerability, and pharmacokinetics of SPR720, a novel oral bacterial DNA gyrase (GyrB) inhibitor for mycobacterial infections","volume":"65","author":"Talley","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120411373932800_dkae046-B15","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3389\/fmicb.2019.00693","article-title":"Mycobacterium avium infection in a C3HeB\/FeJ mouse model","volume":"10","author":"Verma","year":"2019","journal-title":"Front Microbiol"},{"key":"2025120411373932800_dkae046-B16","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1128\/AAC.00459-15","article-title":"Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models","volume":"59","author":"Obregon-Henao","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120411373932800_dkae046-B17","volume-title":"Susceptibility Testing of Mycobacteria, Nocardiae and Other Aerobic Actinomycetes: Approved Standard\u2014Third Edition: M24","author":"CLSI","year":"2018"},{"key":"2025120411373932800_dkae046-B18","volume-title":"Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes\u2014First Edition: M62","author":"CLSI","year":"2018"},{"key":"2025120411373932800_dkae046-B19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-0038-1651491","article-title":"Epidemiology of nontuberculous mycobacteriosis","volume":"39","author":"Adjemian","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"key":"2025120411373932800_dkae046-B20","doi-asserted-by":"crossref","first-page":"623119","DOI":"10.3389\/fimmu.2020.623119","article-title":"The new frontier of host-directed therapies for Mycobacterium avium complex","volume":"11","author":"Crilly","year":"2020","journal-title":"Front Immunol"},{"key":"2025120411373932800_dkae046-B21","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1513\/AnnalsATS.201604-246OC","article-title":"Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases","volume":"13","author":"Morimoto","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2025120411373932800_dkae046-B22","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1128\/AAC.33.9.1493","article-title":"Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis","volume":"33","author":"Takayama","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120411373932800_dkae046-B23","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1021\/acsinfecdis.0c00025","article-title":"Advancement of GyrB inhibitors for treatment of infections caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria","volume":"6","author":"Stokes","year":"2020","journal-title":"ACS Infect Dis"},{"key":"2025120411373932800_dkae046-B24","doi-asserted-by":"crossref","first-page":"e0132121","DOI":"10.1128\/spectrum.01321-21","article-title":"In vitro resistance against DNA gyrase inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus","volume":"10","author":"Aragaw","year":"2022","journal-title":"Microbiol Spectr"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/4\/875\/57130658\/dkae046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/4\/875\/57130658\/dkae046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T16:37:46Z","timestamp":1764866266000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/4\/875\/7613299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2,23]]},"published-print":{"date-parts":[[2024,4,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae046","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,2,23]]}}}